Myeloid cells as target of fingolimod action in multiple sclerosis-Reference-Cited by-同舟云学术

Myeloid cells as target of fingolimod action in multiple sclerosis

Published:2015-11-04 Issue:6 Volume:2 Page:e157
ISSN:2332-7812
Container-title:Neurology - Neuroimmunology Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Di Dario Marco,Colombo Emanuela,Govi Chiara,De Feo Donatella,Messina Maria José,Romeo Marzia,Sangalli Francesca,Moiola Lucia,Rodegher Mariaemma,Martino Gianvito,Martinelli Vittorio,Comi Giancarlo,Farina Cinthia

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Reference36 articles.

1. Multiple sclerosis

2. Principles of bioactive lipid signalling: lessons from sphingolipids

3. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

4. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

5. Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics;International Journal of Molecular Sciences;2024-07-04

2. Span of spleen is associated with disability status in multiple sclerosis: a cross-sectional abdominopelvic ultrasonography study;Scientific Reports;2024-07-03

3. HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity;Journal of Autoimmunity;2023-07

4. iAstrocytes do not restrain T cell proliferation in vitro;BMC Neuroscience;2023-06-07

5. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis;Pharmacology & Therapeutics;2023-06